Emerging utility of once-weekly exenatide in patients with type 2 diabetes.
Emerging utility of once-weekly exenatide in patients with type 2 diabetes.
复制标题
DOI：
10.2147/dmso.s69354
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Rajagopalan S
中科院分区：
文献类型：
--
作者：
Goud A;Zhong J;Rajagopalan S
2 型糖尿病 (T2DM) 是发生心血管疾病 (CVD) 的主要危险因素。由于 T2DM 和 CVD 的发病率不断增加以及这些疾病的共存，多年来已经开发了许多针对并发症的药物。我们重点关注胰高血糖素样肽 1 类似物艾塞那肽长效制剂的功效和安全性。我们的综述重点关注每周一次艾塞那肽的各种里程碑式试验、疗效、安全性和患者观点，描述了其当前和未来在治疗 T2DM 和 CVD 患者中的作用。
Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.